[go: up one dir, main page]

AR069028A1 - Derivados de 1,2,4-triazol pirrolidina fusionados como moduladores de mglur5 - Google Patents

Derivados de 1,2,4-triazol pirrolidina fusionados como moduladores de mglur5

Info

Publication number
AR069028A1
AR069028A1 ARP080104649A ARP080104649A AR069028A1 AR 069028 A1 AR069028 A1 AR 069028A1 AR P080104649 A ARP080104649 A AR P080104649A AR P080104649 A ARP080104649 A AR P080104649A AR 069028 A1 AR069028 A1 AR 069028A1
Authority
AR
Argentina
Prior art keywords
hydrogen
alkyl
mglur5
triazol
modulators
Prior art date
Application number
ARP080104649A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR069028A1 publication Critical patent/AR069028A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • C07D239/36One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un proceso para su preparación y composiciones farmacéuticas que comprenden los compuestos. Reivindicación 1: Un compuesto de fórmula (1) donde: R¹ es metil, halógeno o ciano; R² es hidrógeno o fluoro; R³ es hidrógeno, alquil C₁₋₃, alcoxi C₁₋₃, OR⁵ o NR⁵R⁶; R⁴ es alquil C₁₋₃ o ciclopropil; R⁵ es hidrógeno o alquil C₁₋₃; R⁶ es hidrógeno o alquil C₁₋₃; X es seleccionado del grupo de formulas (2); Y es pirrolidina fusionada con cicloalquil C₃₋₅; Z es un resto del grupo de formulas (3) donde: R⁷ es hidrógeno, alquil C₁₋₃ o alcoxi C₁₋₃; R⁸ es hidrógeno, alquilo C₁₋₃, alcoxi C₁₋₃; R⁹ es hidrógeno, CONR¹⁰R¹¹ o NR¹⁰R¹¹; R¹⁰ es hidrógeno o alquil C₁₋₃; R¹¹ es hidrógeno o alquil C₁₋₃; así como sales, hidratos, isoformas, tautómeros y/o enantiómeros de los mismos farmacéuticamente aceptables.
ARP080104649A 2007-10-26 2008-10-24 Derivados de 1,2,4-triazol pirrolidina fusionados como moduladores de mglur5 AR069028A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98297007P 2007-10-26 2007-10-26

Publications (1)

Publication Number Publication Date
AR069028A1 true AR069028A1 (es) 2009-12-23

Family

ID=40579776

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104649A AR069028A1 (es) 2007-10-26 2008-10-24 Derivados de 1,2,4-triazol pirrolidina fusionados como moduladores de mglur5

Country Status (5)

Country Link
US (1) US20090111820A1 (es)
AR (1) AR069028A1 (es)
CL (1) CL2008003183A1 (es)
TW (1) TW200924774A (es)
WO (1) WO2009054791A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103467362A (zh) * 2013-09-09 2013-12-25 嘉兴学院 具有环丙烷结构s-二苯基脯氨醇类手性有机小分子化合物及其合成方法
CN103450073A (zh) * 2013-09-09 2013-12-18 嘉兴学院 具有环丙烷结构r-二苯基脯氨醇类手性有机小分子化合物及其合成方法
CN103435533A (zh) * 2013-09-09 2013-12-11 嘉兴学院 具有环丙烷结构的s-脯氨醇手性有机小分子化合物及其合成方法
CN103450074A (zh) * 2013-09-09 2013-12-18 嘉兴学院 具有环丙烷结构的r-脯氨醇手性有机小分子化合物及其合成方法
EP2857387A1 (en) 2013-10-07 2015-04-08 Boehringer Ingelheim International Gmbh Process for manufacturing 1,6-dihydro-6-oxo-4-pyridazine carboxylic acid
US11512067B2 (en) * 2017-09-14 2022-11-29 Daiichi Sankyo Company, Limited Compound having cyclic structure

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2324044T3 (es) * 2003-10-08 2009-07-29 Eli Lilly And Company Derivados de pirrol y pirazol como potenciadores de los receptores de glutamato.
SG149900A1 (en) * 2004-02-18 2009-02-27 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
JP2007523183A (ja) * 2004-02-18 2007-08-16 アストラゼネカ アクチボラグ 縮合複素環式化合物及び代謝調節型グルタミン酸受容体アンタゴニストとしてのその使用
EP1809620B1 (en) * 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
PT2000465E (pt) * 2006-03-24 2011-02-10 Eisai R&D Man Co Ltd Derivado de triazolona
TW200811179A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators VI
TW200808800A (en) * 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
TW200811157A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
TW200811137A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators II
TW200811156A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators IV
TW200808777A (en) * 2006-05-05 2008-02-16 Astrazeneca Ab MGLUR5 modulators III
US7774334B2 (en) * 2006-11-27 2010-08-10 Sony Ericsson Mobile Communications Ab Adaptive databases
ES2439246T3 (es) * 2006-12-20 2014-01-22 Merck Sharp & Dohme Corp. Procedimiento de preparación de (1R,2S,5S)-N-[(1S)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2S)-2-[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.0]hexan-2-carboxamida
US8202856B2 (en) * 2007-12-21 2012-06-19 Merck Serono Sa Triazole oxadiazoles derivatives
WO2009115486A1 (en) * 2008-03-18 2009-09-24 Glaxo Group Limited Triazole amide derivatives for use in therapy
GB0814954D0 (en) * 2008-08-18 2008-09-24 Oled T Ltd Compounds having electron transport properties and their preparation and use
ES2561181T3 (es) * 2009-02-05 2016-02-24 Takeda Pharmaceutical Company Limited Compuestos de piridazinona
US20110045101A1 (en) * 2009-05-06 2011-02-24 E.I. Du Pont De Nemours And Company Fungicidal substituted azoles

Also Published As

Publication number Publication date
WO2009054791A1 (en) 2009-04-30
US20090111820A1 (en) 2009-04-30
CL2008003183A1 (es) 2010-01-04
TW200924774A (en) 2009-06-16

Similar Documents

Publication Publication Date Title
AR094346A1 (es) Derivados de azaindol como inhibidores de las proteína quinasas
AR090488A1 (es) Derivados de n-ciclobutilbenzamida, un proceso para su obtencion, intermediarios para su sintesis, composiciones pesticidas y farmaceuticas que los comprenden y metodos para controlar daños debidos a una plaga y/u hongos
CO6220935A2 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
AR069028A1 (es) Derivados de 1,2,4-triazol pirrolidina fusionados como moduladores de mglur5
AR112834A1 (es) Derivados de rapamicina
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR060813A1 (es) Moduladores de mglur5 iii
ES2662444T3 (es) Derivado de piridina
AR087919A1 (es) Heterociclos biciclicos como inhibidores de irak4
AR060598A1 (es) Derivados de anilino-pirimidina inhibidores de proteinquinasas de la ruta nf-kb
AR087711A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y uso de los mismos para el tratamiento de trastornos neurodegenerativos
NI201000059A (es) Inhibidores de la cinasa c-fms.
CO6140060A2 (es) Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5
AR113929A1 (es) Compuestos heterocíclicos
EA201170096A1 (ru) Замещенные производные пиримидона
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
AR091185A1 (es) Derivados de 1,2,4-triazol
AR097755A1 (es) Derivados sustituidos de fenilalanina como moduladores del factor xia
AR096152A1 (es) Derivados de purina
AR110600A1 (es) 5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]piridin-3(2h)-onas sustituidas y su uso como inhibidores de prep
AR121676A1 (es) DERIVADOS DE BENZODIAZEPINAS COMO PAM DE GABAA g1

Legal Events

Date Code Title Description
FB Suspension of granting procedure